Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 700.90 million, a decrease of 5.06% compared to CNY 738.29 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was CNY 42.64 million, representing a slight increase of 1.51% from CNY 42.00 million in the previous year[18]. - The basic earnings per share for the first half of 2022 was CNY 0.1445, down 21.93% from CNY 0.1851 in the same period last year[18]. - The weighted average return on net assets decreased to 2.56%, down 3.59 percentage points from 6.15% in the previous year[18]. - The net cash flow from operating activities was CNY 76.76 million, a significant decrease of 36.54% compared to CNY 120.95 million in the same period last year[18]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was CNY 38.48 million, down 3.64% from CNY 39.94 million in the previous year[18]. - The company achieved operating revenue of CNY 700.90 million in the first half of 2022, a decrease of 5.06% compared to the same period last year[33]. - The net profit attributable to shareholders was CNY 42.64 million, an increase of 1.51% year-on-year[33]. - The company reported a significant increase in long-term borrowings to CNY 290,000,000.00 from CNY 69,790,000.00, representing a growth of approximately 315.5%[102]. - The total profit for the first half of 2022 was RMB 43,853,987.42, a decrease of 15.6% from RMB 51,953,967.38 in the same period last year[104]. Business Strategy and Operations - The company continues to focus on the dual business strategy of "big health + big commerce," with its main businesses being pharmaceuticals, medical devices, and commercial operations[20]. - The pharmaceutical segment includes 80 types of drugs, with core products targeting digestive and respiratory systems, including new generation proton pump inhibitors[21]. - The company has established a sales network covering over 31 provinces, with a self-operated sales team of more than 400 people, achieving product coverage in over 10,000 hospitals[30]. - The medical device business focuses on absorbable biomedical materials, with products like absorbable medical membranes and screws, which are competitive in various surgical fields[24]. - The company is actively expanding its product pipeline in the medical device sector, aiming for breakthroughs in technology and patent reserves[25]. - The company is pursuing a strategy of internal cultivation and external acquisitions to enhance its pharmaceutical retail channel coverage[33]. - The company is restructuring its commercial projects to maximize operational efficiency, focusing on creating a digital and experiential shopping environment[37]. Research and Development - The company has increased R&D expenses by 24.23% to CNY 18.71 million, reflecting a focus on enhancing its product development capabilities[38]. - The company has completed Phase I clinical trials for its global Class I innovative drug DDCI-01 and is initiating Phase II trials for pulmonary arterial hypertension (PAH)[31]. - R&D efforts are focused on both innovative and generic drugs, with an emphasis on managing various risks throughout the development process[47]. - The company capitalizes R&D expenses for new drug development starting from the Phase II clinical trial stage[200]. Financial Position and Assets - The total assets at the end of the reporting period increased by 6.68% to CNY 3.47 billion from CNY 3.25 billion at the end of the previous year[18]. - Cash and cash equivalents increased by 79.18% to ¥487,740,269.85, representing 14.07% of total assets[40]. - The company reported a total of 79,444,603 shares held by Wuhan Hanyang Investment Development Group, the largest unrestricted shareholder[88]. - The company's total liabilities reached CNY 1,691,560,952.93, compared to CNY 1,456,810,918.56, which is an increase of approximately 16.1%[98]. - The total current assets rose to CNY 771,295,013.11 from CNY 611,654,666.66, indicating an increase of about 26.1%[100]. Environmental Management - The company has established a comprehensive environmental management system, significantly enhancing employee awareness of environmental protection[64]. - The company has received the "Environmental Good Enterprise" title in Sichuan Province for two consecutive years[65]. - The company has established an emergency response plan for environmental incidents, which was approved and filed with the local environmental authority[60]. - The wastewater treatment process at Dikang Changjiang includes multiple stages and complies with relevant environmental regulations[58]. Risk Management - The company has not identified any significant risks affecting its ongoing operations during the reporting period[6]. - The company faces risks related to policy changes in the pharmaceutical industry, which could impact operational costs and compliance[46]. - The company is actively managing risks associated with price reductions due to centralized procurement policies, which could affect revenue and profit margins[47]. - The ongoing COVID-19 pandemic presents uncertainties that could impact business operations and consumer demand, necessitating effective cost control measures[48]. Corporate Governance - The company elected five non-independent directors and three independent directors to the board during the 2022 annual general meeting[50]. - The company reported no profit distribution or capital reserve increase plan for the first half of 2022[53]. - There are no changes in the controlling shareholder or actual controller during the reporting period[92]. Accounting and Financial Reporting - The financial statements are prepared based on the assumption of going concern, following the relevant accounting standards and regulations[137]. - The company adheres to the accounting policies that ensure the financial statements reflect a true and complete view of its financial position and performance[138]. - The group determines the scope of consolidated financial statements based on control, which includes the company and all subsidiaries[146]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[143].

Financial Performance - The company's operating revenue for Q1 2022 was ¥357,286,603.21, representing a decrease of 3.02% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥23,258,554.56, an increase of 4.13% year-over-year[3]. - Total revenue for Q1 2022 was CNY 357.29 million, a decrease of 3.03% from CNY 368.40 million in Q1 2021[18]. - Operating profit for Q1 2022 was CNY 22.81 million, compared to CNY 28.11 million in Q1 2021, reflecting a decline of 18.93%[18]. - Net profit for Q1 2022 was CNY 16.51 million, down from CNY 20.11 million in Q1 2021, a decrease of 17.73%[18]. - Net profit for Q1 2022 was ¥16,513,662.17, a decrease of 18.0% compared to ¥20,113,177.22 in Q1 2021[19]. - Revenue from sales of goods and services in Q1 2022 was ¥489,458,093.51, down 19.7% from ¥609,462,096.53 in Q1 2021[22]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥7,030,251.48, a significant decrease of 118.9% compared to the previous year[3]. - Operating cash flow for Q1 2022 showed a net outflow of ¥7,030,251.48, contrasting with a net inflow of ¥37,189,788.78 in Q1 2021[22]. - Cash and cash equivalents increased to CNY 399.45 million as of March 31, 2022, up from CNY 272.21 million at the end of 2021, representing a growth of 46.81%[12]. - Cash and cash equivalents at the end of Q1 2022 increased to ¥456,648,230.29 from ¥148,393,584.61 at the end of Q1 2021, marking a significant improvement[23]. - The company reported a net cash inflow from financing activities of ¥139,778,363.46 in Q1 2022, compared to a net outflow of ¥212,953,231.33 in Q1 2021[23]. - Cash flow from investment activities showed a net outflow of ¥5,501,012.35 in Q1 2022, compared to a net outflow of ¥5,244,103.50 in Q1 2021[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,389,872,276.14, an increase of 4.30% from the end of the previous year[3]. - Total assets as of March 31, 2022, amounted to ¥2,481,045,568.01, an increase from ¥2,374,921,744.36 at the end of 2021[26]. - Total liabilities increased to CNY 1.58 billion as of March 31, 2022, compared to CNY 1.46 billion at the end of 2021, an increase of 8.51%[14]. - Total liabilities as of March 31, 2022, amounted to CNY 977,341,271.28, an increase from CNY 872,481,850.63 at the end of 2021[27]. - Short-term borrowings increased to CNY 233,308,095.89 from CNY 208,297,249.21 at the end of 2021[27]. - Long-term borrowings rose significantly to CNY 278,530,000.00 from CNY 69,790,000.00 at the end of 2021[27]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,242[6]. - The top shareholder, Wuhan Hanyang Investment Development Group Co., Ltd., held 26.93% of the shares[8]. - Shareholders' equity rose to CNY 1.81 billion as of March 31, 2022, compared to CNY 1.79 billion at the end of 2021, reflecting an increase of 0.86%[14]. - Total equity as of March 31, 2022, was CNY 1,503,704,296.73, slightly up from CNY 1,502,439,893.73 at the end of 2021[27]. Expenses - Research and development expenses increased by 58.44%, primarily due to increased R&D spending by the subsidiary Dikon Pharmaceutical[5]. - The company reported a decrease in sales expenses to CNY 9,542,512.19 from CNY 8,171,166.21 in Q1 2021[28]. - Financial expenses decreased significantly to CNY 5,418,457.83 from CNY 11,081,500.83 in Q1 2021, with interest expenses dropping to CNY 8,562,826.72 from CNY 14,056,064.22[28]. Earnings Per Share - Basic earnings per share decreased by ¥0.0237 to ¥0.0788[3]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.0788, down from ¥0.0984 in Q1 2021, reflecting a decline of 20.0%[19]. - The weighted average return on equity decreased by 2.03 percentage points to 1.29%[3].

Financial Performance - The company's operating revenue for 2021 was RMB 1,475,250,374.49, representing a 197.91% increase compared to RMB 495,200,411.33 in 2020[21] - The net profit attributable to shareholders for 2021 was RMB 85,679,135.85, an increase of 88.36% from RMB 45,486,168.42 in 2020[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 55,235,107.87, compared to a loss of RMB 30,403,093.74 in 2020[21] - The net cash flow from operating activities for 2021 was RMB 332,997,567.15, a significant increase of 535.75% from RMB 52,378,354.04 in 2020[21] - The total assets at the end of 2021 were RMB 3,250,183,574.06, slightly up by 0.08% from RMB 3,247,673,152.04 at the end of 2020[21] - The net assets attributable to shareholders increased by 148.62% to RMB 1,647,013,976.29 from RMB 662,462,196.77 in 2020[21] - The basic earnings per share for 2021 were RMB 0.3472, a 73.25% increase from RMB 0.2004 in 2020[22] - The weighted average return on net assets for 2021 was 8.86%, an increase of 1.79 percentage points from 7.07% in 2020[22] Revenue Breakdown - The company achieved a total revenue of RMB 1,475.25 million, an increase of RMB 980.05 million, representing a year-on-year growth of 197.91%[57] - The pharmaceutical segment generated revenue of RMB 1,056.01 million, with a year-on-year increase of 354.22%[57] - The medical device segment reported revenue of RMB 79.36 million, reflecting a year-on-year growth of 226.51%[57] - The exhibition business generated revenue of RMB 74.79 million, marking a year-on-year increase of 75.78%[57] Market Expansion and Acquisitions - The acquisition of Dicon Pharmaceuticals was completed in October 2020, and in 2021, it achieved a net profit of CNY 125.53 million, fulfilling the performance commitment of CNY 90 million for the second year[29] - The company is expanding into the assisted reproduction sector, holding an 80% voting power in Wuhan Tongji Reproductive Medicine Hospital after a 31% stake change[32] - The company established a joint venture with Shanghai United Imaging Healthcare to provide professional medical diagnostic services[32] Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue increase of 20.1% in 2021, reaching CNY 2.93 trillion, with a profit increase of 77.9% to CNY 627.14 billion[34] - The medical device industry in China is projected to exceed CNY 115 billion in revenue in 2021, driven by policy support for innovation and domestic product replacement[35] - The total retail sales of consumer goods in China reached CNY 4,408.23 billion, representing a year-on-year growth of 12.5% and an 8% increase compared to 2019[37] Product Portfolio and Market Position - The company has 80 pharmaceutical products on the market, focusing on areas such as the digestive system, respiratory system, and anti-infection, with core products including Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules[39] - Rabeprazole Sodium Enteric-coated Tablets ranked third in sales in urban retail pharmacies and fifth in public hospitals in 2020[41] - The company’s absorbable medical membrane product revenue ranked second among all anti-adhesion products in China in 2021[45] Research and Development - The company has a strong R&D team focusing on biomedical materials and pharmaceuticals, with ongoing clinical trials for its innovative drug DDCI-01[54] - The company has received a total of 4 invention patents in 2021, including a biodegradable injection filler and a composite material with tumor suppression effects[80] - The company emphasizes the importance of R&D to enhance product lines and ensure sustainable development[108] Operational Efficiency and Cost Management - Operating costs rose to ¥548,738,320.38, reflecting a 273.19% increase from ¥147,040,062.28 year-over-year[59] - Research and development expenses surged by 253.49% to ¥49,036,765.43, primarily due to increased R&D activities at the newly acquired subsidiary, Dikan Pharmaceutical[59] - The gross profit margin for the overall business was 62.80%, with the pharmaceutical segment achieving a gross margin of 54.43%[62] Governance and Management - The board of directors believes that the company's governance structure generally meets the requirements of the Corporate Governance Code for listed companies[143] - The company has established a set of fair and transparent performance evaluation and incentive mechanisms to promote healthy development[144] - The company has established four specialized committees under the board of directors to enhance governance effectiveness[144] Environmental Responsibility - The company has implemented an environmental monitoring plan, with online monitoring devices installed at wastewater discharge points, ensuring compliance with pollution discharge standards[184] - The company has not faced any administrative penalties due to environmental issues during the reporting period[185] - The company has achieved a continuous two-year recognition as a "Good Environmental Enterprise" in Sichuan Province as of December 31, 2021[188] Challenges and Risks - The company faces significant challenges in its business operations due to the uncertainty brought by the recurring COVID-19 pandemic, which has led to reduced consumer travel and a sharp decline in demand for physical retail[141] - The company recognizes the high-risk nature of R&D in the pharmaceutical industry, particularly in innovative drug development and medical device innovation[139] - The company faces potential pricing risks due to the institutionalization of centralized drug procurement, which may affect revenue and profit margins[138]

2021 年第三季度报告 证券代码：600774 证券简称：汉商集团 汉商集团股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期末 | | | --- | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | | 动幅度(%) | | 变动幅度(%) | | | 营业收入 | 371,431,434.41 | 442.70 | 1,109,718,41 ...

2021 年半年度报告 公司代码：600774 公司简称：汉商集团 汉商集团股份有限公司 2021 年半年度报告 1 / 128 2021 年半年度报告 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不分配不转增 否 十、 重大风险提示 报告期内，不存在对公司持续经营产生影响的重大风险。 十一、 其他 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述因存在不确定性，不构成本公司对投资 者的实质性承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 □适用 √不适用 2 / 128 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人阎志、主管会计工作负责人刘传致及会计机构负责人（会 ...

2021 年第一季度报告 二、 公司基本情况 2.1 主要财务数据 本报告期末 上年度末 本报告期末比上年 度末增减(%) 总资产 3,022,947,850.43 3,247,673,152.04 -6.92 归属于上市公司股东的净资 产 684,799,331.97 662,462,196.77 3.37 年初至报告期末 上年初至上年报告期 末 比上年同期增减 (%) 经营活动产生的现金流量净 额 37,189,788.78 -10,809,960.28 年初至报告期末 上年初至上年报告期 末 比上年同期增减 （%） 营业收入 368,401,232.29 37,124,401.79 892.34 归属于上市公司股东的净利 润 22,337,135.20 -27,406,101.76 归属于上市公司股东的扣除 非经常性损益的净利润 22,293,864.59 -27,519,565.26 加权平均净资产收益率 （%） 3.32 -4.51 基本每股收益（元/股） 0.0984 -0.1208 稀释每股收益（元/股） 0.0984 -0.1208 单位：元 币种：人民币 3 / 20 公司代码：600774 ...

Financial Performance - The company's operating revenue for 2020 was approximately ¥495.20 million, a decrease of 57.21% compared to ¥1,157.30 million in 2019[20] - The net profit attributable to shareholders of the listed company was ¥45.49 million, an increase of 52.28% from ¥29.87 million in 2019[20] - The net profit after deducting non-recurring gains and losses was -¥30.40 million, a decrease of 252.58% compared to ¥19.93 million in 2019[20] - The net cash flow from operating activities was ¥52.38 million, a slight increase of 4.25% from ¥50.24 million in 2019[20] - The total assets at the end of 2020 were approximately ¥3.25 billion, an increase of 92.74% from ¥1.68 billion in 2019[20] - The net assets attributable to shareholders of the listed company increased to approximately ¥662.46 million, a growth of 6.72% from ¥620.73 million in 2019[20] - The basic earnings per share for 2020 were ¥0.2004, up 52.28% from ¥0.1316 in 2019[21] - The weighted average return on net assets was 7.07%, an increase of 2.17 percentage points from 4.90% in 2019[21] - The company reported a total revenue of approximately CNY 95.28 million from the digestive system segment, with a year-on-year increase of 92.35%[109] - The respiratory segment generated revenue of approximately CNY 46.10 million, reflecting a year-on-year increase of 75.10%[109] Business Operations - The company completed the acquisition of Chengdu Dikan Pharmaceutical Co., Ltd. for 100% equity in October 2020, marking a strategic expansion into the pharmaceutical sector[26] - The pharmaceutical business includes 80 types of drugs, with core products like Rabeprazole Sodium Enteric-Coated Tablets and Amoxicillin Capsules, which are positioned in high-demand therapeutic areas[28] - The medical device segment focuses on products like absorbable medical membranes and screws for orthopedic surgeries, indicating a strong competitive position in the market[33] - The company’s core product Rabeprazole Sodium ranked fourth in the national market for oral medications in public hospitals, demonstrating strong market presence[32] - The company established a multi-channel distribution network covering all 31 provinces, cities, and autonomous regions in China, enhancing its market reach[50] - The company’s subsidiary, Dikon Zhongke, is the only domestic enterprise capable of mass-producing medical-grade polylactic acid materials, successfully implementing the national "863" high-tech project[36] - The company achieved a net profit of 74.56 million RMB from Dikon Pharmaceutical, exceeding the performance commitment of 70 million RMB for the first year[56] - The company completed the acquisition of 100% equity in Dikon Pharmaceutical, enhancing its core competitiveness in the pharmaceutical and medical device sectors[48] Market Trends - The pharmaceutical manufacturing industry saw a revenue increase of 4.5% year-on-year, indicating a favorable market environment for the company's growth[30] - The medical device industry in China is rapidly growing, with a compound annual growth rate of approximately 15%, and is expected to exceed 1 trillion yuan in revenue from 2021 to 2022[35] - The retail sector in China saw a decline of approximately 4.0% in total retail sales in 2020 due to the pandemic, but the company’s shopping center operations are gradually recovering to pre-pandemic levels[40] - The company is adapting to the post-COVID-19 environment with a gradual recovery in hospital prescription and retail sales channels starting from Q4 2020[32] Research and Development - The company has a strong R&D platform with a focus on innovative drugs, including DDCI-01, which has received clinical trial approvals in China and the U.S.[52] - The company is focusing on accelerating the development of innovative drugs and generic drugs to enhance its product pipeline[112] - The company’s R&D investment accounted for 3.01% of its operating revenue, while the capitalized R&D expenditure ratio was 6.31%[117] - The company reported a total R&D investment for the year was CNY 15,721,102.58, accounting for 3.17% of total revenue[83] - The company has submitted registration applications for several consistency evaluation projects, including Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules[114] Social Responsibility - The company provided significant support during the COVID-19 pandemic, including converting its Wuhan International Exhibition Center into a makeshift hospital with 1,564 beds[57] - The company donated over 10 million yuan worth of supplies, including medical equipment and warm clothing, to hospitals and quarantine sites during the pandemic[179] - The company has actively participated in social responsibility initiatives, including donating 20,000 yuan to the Hubei Poverty Alleviation Foundation and providing 40,000 yuan in donations for environmental protection efforts[177] - The company has established a comprehensive environmental monitoring system, ensuring that all wastewater and air emissions meet regulatory standards[184] Strategic Focus - The company plans to focus on innovation and R&D, particularly advancing the clinical research and registration of the DDCI-01 new drug project in 2021[147] - The company aims to enhance its pharmaceutical product pipeline and accelerate the commercialization of in-progress projects, including the consistency evaluation of existing products[147] - The company is committed to maintaining a dual business model of "big health + big commerce" to drive steady growth in its pharmaceutical business and improve operational efficiency[146] - The company is exploring strategic partnerships and potential acquisitions to enhance its market position and expand its product range[100] Risks and Challenges - The company faces risks from policy changes in the healthcare sector, which could impact its business operations and financial performance[151] - The company anticipates price competition in the pharmaceutical sector due to centralized procurement and healthcare reforms, which may affect revenue and profit margins[151] - The company is actively managing R&D risks associated with long development cycles and regulatory changes in the pharmaceutical industry[152] - The company is recovering from the impacts of the COVID-19 pandemic, with ongoing adjustments to its operations[153]

2020 年第三季度报告 公司代码：600774 公司简称：汉商集团 汉商集团股份有限公司 2020 年第三季度报告 1 / 22 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人阎志、主管会计工作负责人刘传致及会计机构负责人（会计主管人员）张琳保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 9 | 2020 年第三季度报告 一、 重要提示 本报告期末 上年度末 本报告期末比上 年度末增减(%) 总资产 1,775,030,481.88 1,684,962,150.68 5.35 归属于上市公司股东的净资产 550,624,895.50 620,726,02 ...

2020 年半年度报告 公司代码：600774 公司简称：汉商集团 汉商集团股份有限公司 2020 年半年度报告 1 / 123 2020 年半年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 半年度不进行现金分红，也不以资本公积转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告中所涉及的未来计划、发展战略等前瞻性陈述因存在不确定性，不构成本公司 对投资者的实质性承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司持续经营产生影响的重大风险。 十、 其他 □适用 √不适用 2 / 123 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人阎志、主管会计工作负责人刘传致及会计机构负责人（会计主管人员）张琳声明： 保证半年度报告中财务报告的 ...